Intellia Drug Hits Goal in Milestone for Crispr Technology

Intellia Therapeutics Inc. said its gene-editing treatment for a rare swelling disorder met its goal in a late-stage trial, paving the way for the potential first approval of a new, simpler way of modifying DNA.

A single dose of Intellia’s drug freed most patients with the condition from life-threatening swelling attacks, the Boston-area biotech company said Monday. Intellia said it’s seeking regulatory approval to possibly launch the drug in the US in the first half of next year.